Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Non-Current Assets (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Non-Current Assets data on record, last reported at $34.9 million in Q4 2025.

  • For Q4 2025, Non-Current Assets rose 1.42% year-over-year to $34.9 million; the TTM value through Dec 2025 reached $111.4 million, down 27.66%, while the annual FY2025 figure was $34.9 million, 1.42% up from the prior year.
  • Non-Current Assets reached $34.9 million in Q4 2025 per FHTX's latest filing, up from $20.8 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $64.6 million in Q1 2021 and bottomed at $20.8 million in Q3 2025.
  • Average Non-Current Assets over 5 years is $46.8 million, with a median of $48.5 million recorded in 2023.
  • The widest YoY moves for Non-Current Assets: up 1.42% in 2025, down 43.87% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $60.2 million in 2021, then dropped by 11.17% to $53.5 million in 2022, then decreased by 14.49% to $45.7 million in 2023, then decreased by 24.83% to $34.4 million in 2024, then grew by 1.42% to $34.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $34.9 million in Q4 2025, $20.8 million in Q3 2025, and $22.4 million in Q2 2025.